comparemela.com

Latest Breaking News On - Abbvie deutschland gmbh co - Page 9 : comparemela.com

CHMP Recommends Approval of RINVOQ® for the Treatment of Atopic Dermatitis

CHMP Recommends Approval of RINVOQ® for the Treatment of Atopic Dermatitis
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

IMBRUVICA® Plus VENCLEXTA®/VENCLYXTO® Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia Phase 3 GLOW Study

ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary … ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review c

New Data Shows AbbVie s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress - In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2] - The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3] - Full results to be presented at the EULAR 2021 Virtual Congress - RINVOQ is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[2]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.